Skip to content

AbbVie Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Wed, Feb 3, 2027, before the market opens · estimates and history

AbbVie Inc · E.ABBV.MX · Mexico
Use symbol E.ABBV.MX in our API & Excel add-in to retrieve this data ↓
5,545.00
(+0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 26.18%

AbbVie Inc Forecast

AbbVie Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 26.2% a year, a typical one-standard-deviation range is 5,341–5,749 over a week, 5,126–5,964 over a month and 4,093–6,997 over a year. (Signals as of 5 Nov 2026.)

AbbVie Inc Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
AbbVie Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
AbbVie Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
AbbVie Inc
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for AbbVie Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on AbbVie Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

AbbVie Inc Trading Strategies

28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to AbbVie Inc; 2 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 28 strategies holding EEM →

Statistical Distribution of Returns

Plus

How AbbVie Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how AbbVie Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About AbbVie Inc (Mexico)

AbbVie Inc is a listed security in Mexico. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on AbbVie Inc

Frequently asked questions

What is AbbVie Inc?
AbbVie Inc is a listed security in Mexico. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest AbbVie Inc price?
The latest close is 5,545 (5 Nov 2026), +0.02% on the day. The price at the top of the page refreshes during the trading day.
Is AbbVie Inc in an uptrend?
As of 5 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is AbbVie Inc?
20-day realised volatility is 26.2% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 7.6% over a month and 3.7% over a week.
What factors affect AbbVie Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to AbbVie Inc, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade AbbVie Inc?
28 backtested tactical asset allocation strategies trade AbbVie Inc through EEM; 2 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are AbbVie Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of AbbVie Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free AbbVie Inc historical data?
In the Free historical data section of this page: the last 10 years of AbbVie Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free AbbVie Inc historical data (last 10 years)

Browse or instantly download the last 10 years of AbbVie Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ABBV.MX&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-205537
2026-11-195403
2026-11-185405
2026-11-175419
2026-11-135486
2026-11-125513
2026-11-115473
2026-11-105490.3
2026-11-095448
2026-11-065386
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.